Abstract: The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient.

Abstract: A packing box has a bottom panel, end panels raised from first edges of the bottom panel, side panels arranged adjacently to the end panels, edge panels connected to side edges of the end panels via outer panel fold lines, fold-back panels arranged on inner side surfaces of the edge panels, inner panels arranged on inner side surfaces of the end panels, and reinforcing panels continuously formed with the fold-back panels via first fold lines and the inner panels via second fold lines. The reinforcing panel 16 is formed in an inwardly projecting manner between the fold-back panel and the inner panel. Any of the first and second fold lines positioned on a side closer to the outer panel fold line than a projecting top portion is arranged away from the outer panel fold line by a distance.

Abstract: A box includes a front receiving panel, a bottom surface panel, a rear surface panel, a top surface panel, and a front surface panel that are integrally connected one to another. Each pair of bottom side panels, rear side panels, top side panels, and front side panels are integrally connected to the respective sides of each of the bottom, rear, top, and front surface panels. The front receiving panel, the bottom and rear surface panels, and the bottom and rear side panels constitute a tray portion of the box, with the remaining panels constituting a lid portion of the box. A cut line for separating the lid portion from the tray portion is formed to pass through one or both of the rear surface panel and the top surface panel.

Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.

Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.

Abstract: The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient.

Abstract: An aqueous ink for ink jet including a resin particle. The resin particle includes a first layer and a second layer in this order from the inside to the outside thereof. The first layer is composed of a first resin, wherein the proportion of a unit derived from an aromatic-group-containing ethylenically unsaturated monomer in the first resin is 10% by mass or less. The second layer has a tetrahydrofuran-insoluble fraction of 10% by mass or more and is composed of a second resin having a unit derived from an aromatic-group-containing ethylenically unsaturated monomer and a unit derived from an ionic-group-containing ethylenically unsaturated monomer, wherein the proportion of the unit derived from the ionic-group-containing ethylenically unsaturated monomer in the second resin is 3% by mass or more to 70% by mass or less.

Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating cerebral infarction and sequelae associated therewith that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a brain tissue regeneration mechanism by which Muse cells differentiate into nerve cells and the like in damaged brain tissue by administering Muse cells into cerebral parenchyma.

Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating chronic kidney disease that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a renal tissue regeneration mechanism by which Muse cells are made to selectively accumulate at a site of kidney disease and differentiate into cells that compose the kidney by administering Muse cells intravenously to a subject having the aforementioned disease.

Abstract: A packing box has a bottom panel, end panels raised from first edges of the bottom panel, side panels arranged adjacently to the end panels, edge panels connected to side edges of the end panels via outer panel fold lines, fold-back panels arranged on inner side surfaces of the edge panels, inner panels arranged on inner side surfaces of the end panels, and reinforcing panels continuously formed with the fold-back panels via first fold lines and the inner panels via second fold lines. The reinforcing panel 16 is formed in an inwardly projecting manner between the fold-back panel and the inner panel. Any of the first and second fold lines positioned on a side closer to the outer panel fold line than a projecting top portion is arranged away from the outer panel fold line by a distance.

Abstract: Objects of the present invention are to provide a method for directly obtaining pluripotent stem cells which do not have tumorigenic property from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stem cells that can be isolated from body tissue.

Abstract: The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient.

Abstract: An aqueous ink for ink jet including a resin particle. The resin particle includes a first layer and a second layer in this order from the inside to the outside thereof. The first layer is composed of a first resin, wherein the proportion of a unit derived from an aromatic-group-containing ethylenically unsaturated monomer in the first resin is 10% by mass or less. The second layer has a tetrahydrofuran-insoluble fraction of 10% by mass or more and is composed of a second resin having a unit derived from an aromatic-group-containing ethylenically unsaturated monomer and a unit derived from an ionic-group-containing ethylenically unsaturated monomer, wherein the proportion of the unit derived from the ionic-group-containing ethylenically unsaturated monomer in the second resin is 3% by mass or more to 70% by mass or less.

Abstract: A box includes a front receiving panel, a bottom surface panel, a rear surface panel, a top surface panel, and a front surface panel that are integrally connected one to another. Each pair of bottom side panels, rear side panels, top side panels, and front side panels are integrally connected to the respective sides of each of the bottom, rear, top, and front surface panels. The front receiving panel, the bottom and rear surface panels, and the bottom and rear side panels constitute a tray portion of the box, with the remaining panels constituting a lid portion of the box. A cut line for separating the lid portion from the tray portion is formed to pass through one or both of the rear surface panel and the top surface panel.

Abstract: The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient.

Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating cerebral infarction and sequelae associated therewith that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a brain tissue regeneration mechanism by which Muse cells differentiate into nerve cells and the like in damaged brain tissue by administering Muse cells into cerebral parenchyma.

Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating chronic kidney disease that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a renal tissue regeneration mechanism by which Muse cells are made to selectively accumulate at a site of kidney disease and differentiate into cells that compose the kidney by administering Muse cells intravenously to a subject having the aforementioned disease.

Abstract: The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient.

Abstract: A chip stack (11) is configured by stacking at least first, second, and third semiconductor chips (10a, 10b, 10c). The first semiconductor chip (10a) has bump electrodes formed only on one side thereof. The second semiconductor chip (10b) has bump electrodes formed on both sides thereof and they are electrically connected each other. The second semiconductor chip (10b) is stacked on and electrically connected to the first semiconductor chip (10a) through a first solder layer. The third semiconductor chip (10c) has bump electrodes formed on both sides thereof and they are electrically connected each other. Second and third solder layers are formed on the bump electrodes on the both sides of the third semiconductor chip. The third semiconductor chip (10c) is stacked on and electrically connected to the second semiconductor chip (10b) through the third solder layer.

Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.